RESUMEN
We present a case of a young man who developed sudden deterioration in his physical and mental state whilst being treated as an inpatient for substance-induced psychosis. This deterioration was manifested by sudden disorientation, change in behaviour and visual hallucinations. It was only after excluding other potential causes that this presentation was attributed to the regular administration of procyclidine that was being used to counteract the extrapyramidal side effects from antipsychotics. The patient showed a dramatic improvement on stopping procyclidine. This case highlights the importance of awareness of rare adverse drug reactions and the resultant distressing effect for the patient himself.
Asunto(s)
Antipsicóticos , Delirio , Masculino , Humanos , Antagonistas Colinérgicos/efectos adversos , Prociclidina/uso terapéutico , Antipsicóticos/efectos adversos , Alucinaciones/inducido químicamente , Alucinaciones/tratamiento farmacológico , Delirio/inducido químicamenteRESUMEN
This case report highlights the risk of development of Neuroleptic Malignant-Like Syndrome secondary to withdrawal of procyclidine with brief withdrawal of L-dopa and long-term typical antipsychotic depot. The patient responded to reintroduction of procyclidine, sedation and supportive treatment. The mechanism and management of NMS and NMLS is also reviewed. This case emphasises that any changes in antipsychotic and antiparkinsonian medications should be undertaken with extreme caution and patient should be closely monitored for development of NMLS after alteration in these medications.
Asunto(s)
Antipsicóticos , Síndrome Neuroléptico Maligno , Humanos , Antipsicóticos/efectos adversos , Prociclidina/uso terapéutico , Flupentixol/uso terapéutico , Levodopa/efectos adversos , Síndrome Neuroléptico Maligno/etiología , Síndrome Neuroléptico Maligno/tratamiento farmacológicoRESUMEN
Atraumatic trismus can be one of the presentations of medication-induced acute dystonia, particularly by antipsychotics and less commonly antidepressants. A case of an unusual emergency presentation of atraumatic trismus on initiation of duloxetine is reported. The patient was a 40-year-old woman experiencing sudden difficulty in mouth opening and speaking due to a stiffened jaw after taking 5 days of duloxetine prescribed for her fibromyalgia-related chest pain. Assessment of vital signs is prudent to ensure there is no laryngeal involvement. Other physical examinations and her recent investigations were unremarkable. She was treated for acute dystonia and intravenous procyclidine was given together with oral diazepam. Her symptoms improved immediately and her duloxetine was suggested to be stopped. To our knowledge, this is the first case of isolated trismus induced by duloxetine. Clinicians should be aware of this risk, especially considering the limitation of important physiological functions (such as swallowing, eating, etc) associated with this condition.
Asunto(s)
Antidepresivos , Clorhidrato de Duloxetina , Distonía/inducido químicamente , Fibromialgia/tratamiento farmacológico , Trismo/inducido químicamente , Adulto , Antidepresivos/efectos adversos , Antidepresivos/uso terapéutico , Antiparkinsonianos/uso terapéutico , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Clorhidrato de Duloxetina/efectos adversos , Clorhidrato de Duloxetina/uso terapéutico , Femenino , Humanos , Prociclidina/uso terapéuticoRESUMEN
BACKGROUND: Antipsychotic (neuroleptic) medication is used extensively to treat people with serious mental illnesses. However, it is associated with a wide range of adverse effects, including movement disorders. Because of this, many people treated with antipsychotic medication also receive anticholinergic drugs in order to reduce some of the associated movement side-effects. However, there is also a suggestion from animal experiments that the chronic administration of anticholinergics could cause tardive dyskinesia. OBJECTIVES: To determine whether the use or the withdrawal of anticholinergic drugs (benzhexol, benztropine, biperiden, orphenadrine, procyclidine, scopolamine, or trihexylphenidyl) are clinically effective for the treatment of people with both antipsychotic-induced tardive dyskinesia and schizophrenia or other chronic mental illnesses. SEARCH METHODS: We retrieved 712 references from searching the Cochrane Schizophrenia Group's Study-Based Register of Trials including the registries of clinical trials (16 July 2015 and 26 April 2017). We also inspected references of all identified studies for further trials and contacted authors of trials for additional information. SELECTION CRITERIA: We included reports identified in the search if they were controlled trials dealing with people with antipsychotic-induced tardive dyskinesia and schizophrenia or other chronic mental illness who had been randomly allocated to (a) anticholinergic medication versus placebo (or no intervention), (b) anticholinergic medication versus any other intervention for the treatment of tardive dyskinesia, or (c) withdrawal of anticholinergic medication versus continuation of anticholinergic medication. DATA COLLECTION AND ANALYSIS: We independently extracted data from included trials and we estimated risk ratios (RR) with 95% confidence intervals (CIs). We assumed that people who left early had no improvement. We assessed risk of bias and created a 'Summary of findings' table using GRADE. MAIN RESULTS: The previous version of this review included no trials. We identified two trials that could be included from the 2015 and 2017 searches. They randomised 30 in- and outpatients with schizophrenia in the USA and Germany. Overall, the risk of bias was unclear, mainly due to poor reporting: allocation concealment was not described; generation of the sequence was not explicit; studies were not clearly blinded; and outcome data were not fully reported.Findings were sparse. One study reported on the primary outcomes and found that significantly more participants allocated to procyclidine (anticholinergic) had not improved to a clinically important extent compared with those allocated to isocarboxazid (MAO-inhibitor) after 40 weeks' treatment (1 RCT, n = 20; RR 4.20, 95% CI 1.40 to 12.58; very low quality evidence); that there was no evidence of a difference in the incidence of any adverse effects (1 RCT, n = 20; RR 0.33, 95% CI 0.02 to 7.32; very low quality evidence); or acceptability of treatment (measured by participants leaving the study early) (1 RCT, n = 20; RR 0.33, 95% CI 0.02 to 7.32; very low quality evidence). The other trial compared anticholinergic withdrawal with anticholinergic continuation and found no evidence of a difference in the incidence of acceptability of treatment (measured by participants leaving the study early) (1 RCT, n = 10; RR 2.14, 95% CI 0.11 to 42.52; very low quality evidence).No trials reported on social confidence, social inclusion, social networks, or personalised quality of life - outcomes designated important to patients. No studies comparing either i. anticholinergics with placebo or no treatment, or ii. studies of anticholinergic withdrawal, were found that reported on the primary outcome 'no clinically important improvement in TD symptoms and adverse events'. AUTHORS' CONCLUSIONS: Based on currently available evidence, no confident statement can be made about the effectiveness of anticholinergics to treat people with antipsychotic-induced tardive dyskinesia. The same applies for the withdrawal of such medications. Whether the withdrawal of anticholinergics may benefit people with antipsychotic-induced TD should be evaluated in a parallel-group, placebo-controlled randomised trial, with adequate sample size and at least 6 weeks of follow-up.
Asunto(s)
Antipsicóticos/efectos adversos , Antagonistas Colinérgicos/uso terapéutico , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Biperideno/efectos adversos , Biperideno/uso terapéutico , Antagonistas Colinérgicos/efectos adversos , Discinesia Inducida por Medicamentos/etiología , Humanos , Isocarboxazida/efectos adversos , Isocarboxazida/uso terapéutico , Prociclidina/efectos adversos , Prociclidina/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Esquizofrenia/tratamiento farmacológico , Privación de TratamientoRESUMEN
A 27-year-old man presented to hospital after smoking a legal high named 'Clockwork Orange'. He suffered dystonia, acute kidney injury, rhabdomyolysis, lactic acidosis and a troponin rise. He was treated with procyclidine and intravenous fluids.
Asunto(s)
Cannabinoides/efectos adversos , Distonía/inducido químicamente , Trastornos Relacionados con Sustancias/complicaciones , Acidosis Láctica/inducido químicamente , Lesión Renal Aguda/inducido químicamente , Adulto , Antiparkinsonianos/uso terapéutico , Humanos , Legislación de Medicamentos , Masculino , Prociclidina/uso terapéutico , Rabdomiólisis/inducido químicamente , Trastornos Relacionados con Sustancias/tratamiento farmacológico , Troponina/sangreRESUMEN
A treatment regimen consisting of HI-6, levetiracetam, and procyclidine (termed the triple regimen) has previously been shown to work as a universal therapy against soman poisoning in rats, since it has capacities to function as both prophylactic and therapeutic measure. The purpose of the present study was to examine whether the triple regimen may have antidotal efficacy against intoxication by other classical nerve agents than soman. The treatment was given 1 and 5 min after exposure to a supralethal dose of nerve agents, and the results showed that the triple regimen successfully prevented or terminated seizures and preserved the lives of rats exposed to 5×LD50 of soman, sarin, cyclosarin, or VX, but solely 3×LD50 of tabun was managed by this regimen. To meet the particular antidotal requirements of tabun, the triple regimen was reinforced with obidoxime and was made to a quadruple regimen that effectively treated rats intoxicated by 5×LD50 of tabun. The rats recovered very well and the majority gained pre-exposure body weight within 7 days. Neuropathology was seen in all groups regardless of whether the rats seized or not. The most extensive damage was produced by sarin and cyclosarin. Differentiation between the nerve agents' potency to cause lesions was probably seen because the efficacious treatments ensured survival of supralethal poisoning. A combination of 2 oximes and 2 anticonvulsants may be a prerequisite to counteract effectively high levels of poisoning by any classical nerve agent.
Asunto(s)
Antídotos/uso terapéutico , Agentes Nerviosos/toxicidad , Intoxicación por Organofosfatos/tratamiento farmacológico , Intoxicación por Organofosfatos/etiología , Soman/toxicidad , Animales , Anticonvulsivantes/uso terapéutico , Peso Corporal/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/patología , Encéfalo/fisiopatología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Electroencefalografía , Dosificación Letal Mediana , Levetiracetam , Masculino , Organofosfatos/toxicidad , Compuestos Organofosforados/toxicidad , Compuestos Organotiofosforados/toxicidad , Oximas/uso terapéutico , Piracetam/análogos & derivados , Piracetam/uso terapéutico , Prociclidina/uso terapéutico , Compuestos de Piridinio/uso terapéutico , Ratas , Ratas Wistar , Convulsiones/inducido químicamente , Convulsiones/tratamiento farmacológicoRESUMEN
During the establishment of a research branch, all relevant matters encountered will be of interest to study. After having acquired a body of basal knowledge, it becomes possible to derive ideas or hypotheses for further elaboration of information. The purpose of the present study was to show that therapies for nerve agent poisoning based on specific neuropharmacological approaches can have greater probability for being successful than treatment regimens based on fragmental research or serendipitous discoveries. By following the guidelines for research in experimental epilepsy, neuronal target areas for nerve agents have been identified through lesion studies, and critical receptors for pharmacological treatment have been specified through microinfusion studies of rats. Subsequent experimentations have shown that the results achieved from microinfusion studies are transferable to systemic administration. It is demonstrated that a treatment regimen developed through the novel approach is more efficacious than regimens derived from conventional research on countermeasures. A therapy consisting of HI-6, levetiracetam, and procyclidine that has been worked out along the new lines, exerts powerful anticonvulsant capacity and appears to have universal utility as a stand-alone therapy against soman intoxication in rats. It would be of great interest to examine whether the latter findings can be expanded to other animal species than rats and other classical nerve agents than soman.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Antídotos/uso terapéutico , Encéfalo/efectos de los fármacos , Encéfalo/fisiopatología , Intoxicación por Organofosfatos , Convulsiones/inducido químicamente , Convulsiones/tratamiento farmacológico , Animales , Anticonvulsivantes/administración & dosificación , Antídotos/administración & dosificación , Colinérgicos/administración & dosificación , Colinérgicos/uso terapéutico , Humanos , Levetiracetam , Oximas/administración & dosificación , Oximas/uso terapéutico , Piracetam/administración & dosificación , Piracetam/análogos & derivados , Piracetam/uso terapéutico , Prociclidina/administración & dosificación , Prociclidina/uso terapéutico , Compuestos de Piridinio/administración & dosificación , Compuestos de Piridinio/uso terapéutico , RatasRESUMEN
A treatment regimen consisting of HI-6, scopolamine, and physostigmine (termed the physostigmine regimen) has been based on the serendipitous discovery that it exerts powerful antidotal effects against high levels of soman poisoning if it is administered 1 min after exposure. A medical therapy with corresponding efficacy, but without the time limitation of the latter regimen, has been developed through studies of microinfusions of anticonvulsants into seizure controlling sites in the forebrain of rats. From these studies procyclidine emerged as the most potent anticonvulsant, and its potency was further enhanced when being combined with the antiepileptic levetiracetam during systemic administration. In the present study, the capacity of HI-6, levetiracetam, and procyclidine (termed the procyclidine regimen) was tested against that of the physostigmine regimen. The results showed that both regimens were very effective against supralethal doses of soman (3, 4, 5 × LD50) when given 1 and 5 min after intoxication. When the treatments were administered 10 and 14 or 20 and 24 min after soman exposure, only the procyclidine regimen was able to terminate seizures and preserve lives. When used as prophylactic therapies, both regimens protected equally well against seizures, but only the procyclidine regimen provided neuroprotection. The procyclidine regimen has apparently capacities to serve as a universal therapy against soman intoxication in rats.
Asunto(s)
Fármacos Neuroprotectores/uso terapéutico , Fisostigmina/uso terapéutico , Prociclidina/uso terapéutico , Convulsiones/inducido químicamente , Convulsiones/prevención & control , Soman/envenenamiento , Animales , Anticonvulsivantes/uso terapéutico , Masculino , Ratas , Ratas Wistar , Factores de Tiempo , Resultado del TratamientoRESUMEN
A transdermal patch system containing procyclidine, an N-methyl-d-aspartate receptor antagonist possessing anticholinergic action, and physostigmine, a reversible cholinesterase inhibitor, was developed, and its prophylactic efficacy against soman intoxication was investigated. Male rhesus monkeys were shaved on the dorsal area, attached with a matrix-type patch with various sizes (2×2 to 7×7 cm) for 24 or 72 h, and challenged with 2×LD50 doses (13µg/kg) of soman. The smallest patch size for the protection against lethality induced by soman intoxication was 3×3cm, resulting in blood procyclidine concentration of 10.8 ng/ml, blood physostigmine concentration of 0.54 ng/ml, which are much lower concentrations than maximum sign-free doses, and blood cholinesterase inhibition of 42%. The drug concentrations and enzyme inhibition rate corresponding to a diverging point of survivability were presumably estimated to be around 7 ng/ml for procyclidine, 0.35 ng/ml for physostigmine, and 37% of enzyme inhibition. Separately, in combination with the patch treatment, the post treatment consisting of atropine (0.5 mg/kg) plus 1-[([4-(aminocarbonyl)pyridinio]methoxy)methyl]-2-[(hydroxyimino)methyl]pyridinium (HI-6, 50 mg/kg) exerted protection against 5×LD50 challenge of soman, which means the posttreatment remarkably augmented the efficacy of the patch. Additionally, it was found that brain injuries induced by soman toxicity were effectively prevented by the patch treatment according to histopathological examinations. These results suggest that the patch system could be an effective alternative for diazepam, an anticonvulsant, and the current pyridostigmine pretreatment, and especially in combination with atropine plus HI-6, could be a choice for quality survival from nerve-agent poisoning.
Asunto(s)
Inhibidores de la Colinesterasa/toxicidad , Inhibidores de la Colinesterasa/uso terapéutico , Antagonistas Muscarínicos/uso terapéutico , Fisostigmina/uso terapéutico , Intoxicación/prevención & control , Prociclidina/uso terapéutico , Soman/toxicidad , Parche Transdérmico , Acetilcolinesterasa/metabolismo , Animales , Antídotos/administración & dosificación , Antídotos/uso terapéutico , Atropina/uso terapéutico , Encéfalo/efectos de los fármacos , Encéfalo/patología , Sustancias para la Guerra Química/toxicidad , Inhibidores de la Colinesterasa/administración & dosificación , Inhibidores de la Colinesterasa/sangre , Reactivadores de la Colinesterasa/uso terapéutico , Dosificación Letal Mediana , Macaca mulatta , Masculino , Antagonistas Muscarínicos/administración & dosificación , Antagonistas Muscarínicos/sangre , Oximas/uso terapéutico , Fisostigmina/administración & dosificación , Fisostigmina/sangre , Prociclidina/administración & dosificación , Prociclidina/sangre , Compuestos de Piridinio/uso terapéuticoRESUMEN
Identification of critical receptors in seizure controlling brain regions may facilitate the development of more efficacious pharmacological therapies against nerve agent intoxication. In the present study, a number of drugs with anticonvulsant potency were microinfused into the perirhinal cortex (PRC) or posterior piriform cortex (PPC) in rats. The drugs used exert cholinergic antagonism (scopolamine), glutamatergic antagonism (ketamine, NBQX), both cholinergic and glutamatergic antagonism (procyclidine, caramiphen), or GABAergic agonism (muscimol). The results showed that in the PRC anticonvulsant efficacy against soman-induced seizures (subcutaneously administered) was achieved by procyclidine or NBQX, but not by ketamine, scopolamine, caramiphen, or muscimol (Experiment 1). Hence, both muscarinic and glutamatergic NMDA receptors had to be antagonized simultaneously or AMPA receptors alone, suggesting increased glutamatergic activation in the PRC before onset of seizures. In the PPC, anticonvulsant effects were assured by scopolamine or muscimol, but not by procyclidine, caramiphen, NBQX, or ketamine (Experiment 2). Thus, muscarinic and GABA(A) receptors appear to be the critical ones in the PPC. Microinfusion of soman into the PRC or PPC resulted in sustained seizure activity in the majority of the rats of both infusion categories. The rhinal structures encompassed in this study apparently have critical functions as both control and trigger sites for nerve agent-evoked seizures.
Asunto(s)
Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/fisiología , Convulsiones/inducido químicamente , Convulsiones/patología , Soman , Animales , Anticonvulsivantes/farmacología , Modelos Animales de Enfermedad , Electroencefalografía/métodos , Agonistas del GABA/efectos adversos , Masculino , Antagonistas Muscarínicos/efectos adversos , Muscimol/efectos adversos , Prociclidina/uso terapéutico , Quinoxalinas/farmacología , Ratas , Ratas Wistar , Escopolamina/efectos adversos , Convulsiones/tratamiento farmacológico , Estadísticas no ParamétricasRESUMEN
OBJECTIVES: Irritable bowel syndrome (IBS) is a functional disorder, which has recently been linked to immune activation. We tested the hypothesis that the pro-inflammatory cytokine profile in IBS is driven by the cholinergic system and determined if the responses are mediated by muscarinic receptors. METHODS: Eighty-eight subjects took part in two studies, 37 IBS patients (Rome II), 14 depressed patients, and 37 healthy volunteers. Eighteen IBS patients had diarrhea predominant IBS, 14 were alternators, and 5 were predominantly constipated. In study 1, blood was drawn for baseline measurement of growth hormone (GH) and cytokines IL-6, IL-8, and IL-10. Pyridostigmine 120 mg was administered orally and further blood sampling took place for 180 min. In study 2, patients with IBS, depressed patients, and healthy subjects underwent the pyridostigmine test on two separate occasions with procyclidine (antimuscarinic) pre-treatment on one test occasion. Both GH and IL-6 were monitored. RESULTS: In study 1, baseline IL-6 (P= 0.003) and IL-8 levels (P= 0.001) were higher in IBS than in controls. Pyridostigmine stimulated the release of IL-6 and GH, but not IL-8 or IL-10; these responses were significantly augmented in IBS patients relative to controls. The IL-6 level following pyridostigmine administration correlated significantly with the symptom score (P < 0.01). In study 2, IL-6 rose following pyridostigmine in IBS but not depression and procyclidine blocked the rise. The GH response was abolished by procyclidine in all three groups. CONCLUSIONS: IBS and major depression are characterized by a pro-inflammatory profile, whereas IBS patients alone exhibit an exaggerated muscarinic receptor-mediated IL-6 response.
Asunto(s)
Interleucina-6/sangre , Síndrome del Colon Irritable/sangre , Receptores Muscarínicos/metabolismo , Dolor Abdominal/sangre , Dolor Abdominal/diagnóstico , Dolor Abdominal/etiología , Administración Oral , Adolescente , Adulto , Biomarcadores/metabolismo , Inhibidores de la Colinesterasa/administración & dosificación , Relación Dosis-Respuesta a Droga , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Interleucina-10/sangre , Interleucina-8/sangre , Síndrome del Colon Irritable/complicaciones , Síndrome del Colon Irritable/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Antagonistas Muscarínicos/uso terapéutico , Dimensión del Dolor , Prociclidina/uso terapéutico , Pronóstico , Bromuro de Piridostigmina/administración & dosificación , Radioinmunoensayo , Receptores Muscarínicos/efectos de los fármacosRESUMEN
INTRODUCTION: Priapism is a urological emergency which is commonly classified into low-flow and high-flow priapism. Immediate intervention is required for low-flow cases as the development of ischaemia ultimately leads to long-term erectile dysfunction. Stuttering or recurrent priapism is less well understood. This subtype is characterised by short-lived painful erections and is commonly encountered in patients with sickle cell disease. METHODS: A systematic review of the treatment options available for stuttering priapism is presented combined with our own experience in managing this condition over a period of 25 years. RESULTS: Although numerous medical treatment options have been reported, the majority are through small trials or anecdotal reports. CONCLUSIONS: Stuttering priapism is a condition which is still not well understood and there is no standardised algorithm for the management of this condition. A multicentre randomised trial is required to evaluate the treatment options.
Asunto(s)
Hormonas/uso terapéutico , Orquiectomía/métodos , Prótesis de Pene , Priapismo/terapia , Anemia de Células Falciformes/complicaciones , Digoxina/uso terapéutico , Sistemas de Liberación de Medicamentos/métodos , Etilefrina/uso terapéutico , Humanos , Masculino , Inhibidores de Fosfodiesterasa/uso terapéutico , Priapismo/etiología , Prociclidina/uso terapéutico , Seudoefedrina/uso terapéutico , Terbutalina/uso terapéutico , Resultado del TratamientoRESUMEN
We report a case of abdominal pain with rigidity, mimicking an acute abdomen, caused by metoclopramide, a common anti-emetic drug. Extrapyramidal symptoms are commonly reported side-effects of this medication. They generally include involuntary movements of limbs, torticollis, oculogyric crisis, rhythmic protrusion of tongue, trismus, or dystonic reactions resembling tetanus, etc. Abdominal rigidity due to this medication, resembling an acute abdomen, has not been reported previously. This case report illustrates the importance of considering medication side-effects when evaluating a patient with abdominal pain and rigidity.
Asunto(s)
Abdomen Agudo/diagnóstico , Dolor Abdominal/inducido químicamente , Dolor Abdominal/diagnóstico , Antieméticos/efectos adversos , Metoclopramida/efectos adversos , Músculos Abdominales , Adulto , Antieméticos/uso terapéutico , Antimaláricos/uso terapéutico , Cloroquina/uso terapéutico , Diagnóstico Diferencial , Servicio de Urgencia en Hospital , Humanos , Malaria Vivax/tratamiento farmacológico , Masculino , Metoclopramida/uso terapéutico , Antagonistas Muscarínicos/uso terapéutico , Rigidez Muscular/inducido químicamente , Rigidez Muscular/tratamiento farmacológico , Prociclidina/uso terapéuticoRESUMEN
The purpose of the present study was to examine the efficacy of a triple combination of drugs with adequate anticonvulsant effects and a dual combination with inadequate anticonvulsant effects followed by adjunct therapy. The results showed that combined intramuscular injections of HI-6 (42 mg/kg), atropine (14 mg/kg), and avizafone (3 mg/kg) administered 1, 16, and 31 min. after exposure to a soman dose of 4 x LD(50) completely terminated seizures with a moderate mortality rate (25%). When the soman dose was lowered to 3 x LD(50) the anticonvulsant effect was complete, and no rats died within 24 hr. Rats challenged with 5 x LD(50) of soman all died within 10 min. Without avizafone in the combination, seizures induced by 3 or 4 x LD(50) of soman could not be terminated unless an adjunct therapy consisting of procyclidine (6 mg/kg), diazepam (10 mg/kg), and pentobarbital (30 kg/kg) was given, and the mortality rate was comparatively high (78%). Administration of the adjunct therapy alone 6-16 min. after 4 x LD(50) of soman stopped the seizure activity, but all the rats died within 24 hr. Marked neuropathology was found in the piriform cortex and amygdala, whereas the hippocampal CA1 field was effectively protected when both the triple combination and the dual combination plus adjuncts had stopped seizures 35-55 min. after onset. It is concluded that termination of soman-induced seizures at an early stage (<20 min.) is crucial to avoid neuronal pathology.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Convulsiones/tratamiento farmacológico , Soman/toxicidad , Animales , Atropina/uso terapéutico , Encéfalo/efectos de los fármacos , Encéfalo/patología , Diazepam/uso terapéutico , Dipéptidos/uso terapéutico , Combinación de Medicamentos , Dosificación Letal Mediana , Masculino , Oximas , Pentobarbital/uso terapéutico , Prociclidina/uso terapéutico , Compuestos de Piridinio/uso terapéutico , Ratas , Ratas Wistar , Convulsiones/inducido químicamente , Convulsiones/mortalidadRESUMEN
Individuals with schizophrenia, compared to healthy individuals, are known to exhibit deficient prepulse inhibition (PPI) of the startle response as well as reduced performance on the antisaccade task. There is evidence for genetic transmission of both PPI and antisaccadic abnormalities in schizophrenia. It has been suggested that PPI and antisaccade measures identify separate endophenotypes, on the basis of a lack of relationship between PPI and antisaccade deficits in patients with schizotypal personality disorder. However, given that patients with schizotypal personality disorder are unlikely to manifest all the abnormalities associated with schizophrenia, it is important to determine that there is no relationship present between these two abnormalities in people affected with schizophrenia. The main objective of this investigation therefore was to establish the lack of the association between PPI and antisaccade deficits in schizophrenia in two independent studies. Study 1 involved 39 patients with schizophrenia and 14 healthy controls and study 2 involved 35 patients with schizophrenia and 22 healthy controls. PPI (uninstructed paradigm) of the acoustically elicited startle (eye blink) was measured electromyographically. Antisaccadic eye movements (standard, non-overlap version) were measured using infrared oculography. Patients displayed reduced PPI and a lower percentage of correct antisaccades relative to healthy controls in both studies. As expected, no relationship occurred between PPI and the percentage of correct antisaccade responses in either group. It is concluded that PPI and antisaccade abnormalities in schizophrenia represent separate endophenotypes, reflecting the functions of different genetic aetiologies and different or only partially overlapping neural systems.
Asunto(s)
Frecuencia Cardíaca/fisiología , Inhibición Psicológica , Fenotipo , Movimientos Sacádicos/fisiología , Esquizofrenia/genética , Adulto , Anciano , Parpadeo/efectos de los fármacos , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Electromiografía , Electrooculografía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antagonistas Muscarínicos/farmacología , Antagonistas Muscarínicos/uso terapéutico , Prociclidina/farmacología , Prociclidina/uso terapéutico , Reflejo de Sobresalto/efectos de los fármacos , Movimientos Sacádicos/efectos de los fármacos , Esquizofrenia/diagnóstico , Esquizofrenia/tratamiento farmacológicoRESUMEN
The combined effects of physostigmine and procyclidine (antagonizing muscarinic, nicotinic, and NMDA receptors) were tested against various doses of soman. Physostigmine (0.1 mg/kg) in combination with procyclidine doses of 1, 3, or 6 mg/kg effectively prevented the development of convulsions and hippocampally monitored seizures when the doses of soman were 1.3, 1.6, or 2 x LD50, respectively. Results from [(3)H]MK-801-binding experiments showed that procyclidine inhibits the phencyclidine site at the NMDA receptor in a concentration-dependent manner. Physostigmine (0.1 mg/kg) and procyclidine in a dose of 1 mg/kg did not prevent convulsions or seizures when the soman dose was 1.6 x LD50. Subsequent treatment with scopolamine in doses of 0.5 or 1 mg/kg immediately after (3 min) seizure onset showed that only the highest dose produced a reliable termination. When scopolamine (1 mg/kg) was given later (10 min) after onset of seizures, no effect was obtained. The sustained seizures were subsequently treated with diazepam (10 mg/kg) and pentobarbital (30 mg/kg) and finally terminated 25 min after onset. In rats given inadequate prophylaxis, both modified convulsions and seizures were seen. It is suggested that moderate doses of prophylactics should be preferred to avoid adverse effects on cognitive functions because insufficient prophylaxis can be compensated for by adjunct treatment.
Asunto(s)
Inhibidores de la Colinesterasa/uso terapéutico , Convulsivantes/toxicidad , Hipocampo/efectos de los fármacos , Antagonistas Muscarínicos/uso terapéutico , Convulsiones/inducido químicamente , Soman/toxicidad , Animales , Inhibidores de la Colinesterasa/administración & dosificación , Convulsivantes/administración & dosificación , Convulsivantes/antagonistas & inhibidores , Maleato de Dizocilpina/metabolismo , Relación Dosis-Respuesta a Droga , Electroencefalografía , Hipocampo/metabolismo , Hipocampo/patología , Masculino , Fármacos Neuroprotectores/metabolismo , Fisostigmina/uso terapéutico , Prociclidina/uso terapéutico , Ratas , Ratas Wistar , Escopolamina/uso terapéutico , Convulsiones/prevención & control , Soman/administración & dosificación , Soman/antagonistas & inhibidoresRESUMEN
Smooth pursuit eye movement (SPEM) and antisaccade deficits are observed in the schizophrenia spectrum and have been used to study the pathophysiology as well as the genetic basis of this condition. The neurotransmitter acetylcholine has been implicated in a number of cognitive processes thought to underlie SPEM and antisaccade performance. This study investigates effects on eye movements of procyclidine, an anticholinergic drug often administered to schizophrenic patients. A total of 13 patients completed a double-blind placebo-controlled crossover design, receiving 15 mg procyclidine and placebo. Seven participants received procyclidine first and placebo second, six participants were tested in the reverse order. SPEM and antisaccade (as well as fixation and prosaccade) eye movements were recorded using infrared oculography. Results showed that procyclidine overall, relative to placebo, mildly worsened SPEM performance, as indicated by nonsignificantly reduced gain (p=0.08) and increased frequency of intrusive anticipatory saccades during pursuit (p=0.06). A significant interaction of group and order of administration indicated that procyclidine increased the rate of antisaccade reflexive errors only when administered first; the opposite pattern was observed when placebo was administered first, likely due to the operation of practice effects at second assessment. These findings indicate that acute administration of a clinically relevant dose of procyclidine leads to mild impairments in eye movement performance in schizophrenic patients, suggesting the need to consider this compound in oculomotor studies in schizophrenia. The action of this anticholinergic drug on oculomotor performance is consistent with the hypothesized role of the cholinergic system in the cognitive mechanisms of attention and working memory, processes thought to underlie SPEM and antisaccade performance. Effects of order of administration and practice on the antisaccade task suggest that these factors need to be taken into consideration in future pharmacological studies.
Asunto(s)
Antiparkinsonianos/farmacología , Movimientos Oculares/efectos de los fármacos , Prociclidina/farmacología , Esquizofrenia/fisiopatología , Adulto , Análisis de Varianza , Antiparkinsonianos/uso terapéutico , Estudios Cruzados , Método Doble Ciego , Electrooculografía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Placebos , Prociclidina/uso terapéutico , Desempeño Psicomotor , Seguimiento Ocular Uniforme/efectos de los fármacos , Movimientos Sacádicos/efectos de los fármacos , Esquizofrenia/tratamiento farmacológicoRESUMEN
Procyclidine and ethopropazine, widely used as anti-parkinsonian agents because of their anti-cholinergic action, are also known to have NMDA antagonist properties. Unlike other NMDA antagonists, these agents-because of their anti-cholinergic action-are devoid of neurotoxic side effects. In the present study, we used a sciatic nerve ligation model that produces a hyperalgesic (neuropathic pain) state in adult rats to evaluate the ability of procyclidine or ethopropazine, either alone or in combination with an alpha(2) adrenergic agonist, to ameliorate neuropathic pain. We found that both procyclidine and ethopropazine alleviated thermal hyperalgesia in a dose dependent manner; when a marginally effective dose of these agents was combined with an ineffective dose of an alpha(2) adrenergic agonist (clonidine or guanabenz), the combination therapy provided effective and long-lasting relief from neuropathic pain. In addition, the combination therapy was free from neurotoxic or behavioral side effects, and hyperactivity, a side effect associated with procyclidine monotherapy, was counteracted by clonidine.
Asunto(s)
Antiparkinsonianos/farmacología , Hiperalgesia/tratamiento farmacológico , Enfermedades del Sistema Nervioso Periférico/tratamiento farmacológico , Fenotiazinas/uso terapéutico , Prociclidina/uso terapéutico , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Agonistas alfa-Adrenérgicos/farmacología , Animales , Clonidina/farmacología , Constricción Patológica/complicaciones , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Femenino , Guanabenzo/farmacología , Hiperalgesia/etiología , Hiperalgesia/fisiopatología , Ligadura , Dimensión del Dolor , Enfermedades del Sistema Nervioso Periférico/etiología , Enfermedades del Sistema Nervioso Periférico/fisiopatología , Ratas , Ratas Sprague-Dawley , Receptores Adrenérgicos alfa 2/efectos de los fármacos , Nervio CiáticoRESUMEN
A patient underwent an emergency Caesarean section under general anaesthesia for an antepartum haemorrhage. Following delivery of a live infant, cyclizine was administered in accordance with departmental anti-emetic protocol. On awakening she was confused, slow to articulate and had slurred speech. A computed tomography (CT) scan, which was performed to exclude an intracranial event, was normal. Her symptoms were suggestive of a lingual-facial-buccal dyskinesia as seen with dopamine antagonists. A presumptive diagnosis of a dystonic reaction to cyclizine was made. She received two doses of procyclidine before her symptoms completely resolved. Cyclizine has had a resurgence in popularity owing to the recent withdrawal of droperidol and anaesthetists should be aware that, although extremely rare, dystonic reactions may occur with this agent.